

Page: 1 of 5

All ISI (Adverse Events and Special Situations) must be reported to Sanofi within agreed timelines. Please complete all fields where information is available. **Fields to be completed in compliance with local data privacy regulation.

G	eneral Inform	nation									
lni	tial Report		Country of occurrence								
	nofi Case ID applicable))			Service Provider or Collecting Org /First and Last Name / Phone or Email						
Re	gistry/Digital	Media ID					ISI identifi	icatio	n / receipt	date	
							Local PV R	eceipt	ot Date (if applicable)		
Are you responding to Sanofi PV Follow-up Request?					Are you respon Follow-up Ques					fi PV	
Re	eporter Infori	mation**	(the person who	reporte	d the ISI to	you)					
Name or Initials				Postal Address							
He	althcare Profes	sional?									
Те	lephone/Fax										
En	nail Address			Country							
Re	porter Type			If 'Other' please specify							
Co	onsent for Fo	ollow-Up	Information	for IS	SI report	ed by Co	nsumers	**			
	the patient provided		nsent for Sanofi to cor	ntact his,	/her treating	he alth care pro	ofessional (HCP) about	the reporte	d ISI in orde	r to obtain
HCP First and Last Name				HCP Postal A			tal Addres	I Address			
HCP Email Address											
HCP Telephone/Fax			HCP Country								
Pa	tient Informa	ntion**(prov	vide Age/Age Group at	time of	adverse ever	nt)					
Name (First and Last Name)				Initial				ials		Gende	r
Pa	tient ID (include	Center ID if	applicable)						е		
Da	te of Birth			A					e Group		
Pregnant Breastfeeding:			Breastfeeding:	Was there parental drug exposure?							
Re	levant Medical	l History/F	Risk factors (ple	ease add any additional information on Page 5)							
No	History/Risk fa	ctors			Start Da	te Stop Da	ate Ongo	ing?	Notes		
1											
2											
3											
		St (please a	dd any additional ii						T		
No	Test Name	Test Name			Test Date Test Res		ılt Test Unit		Notes		
1											
2											
3											
Re	levant Investi	gations (p	lease add any addi	tional ii	nformation	on Page 5)					
No	Investigations			Date	е	Result			Notes	S	
1											



Page: 2 of 5

Suspect Product 1			
Trade Name 1		Active Ingredient 1	
Formulation 1		Indication 1	
Location of Administration 1		Route of administration 1	
Dosage Details 1 (dose, unit)		Action taken 1	
Dosage Frequency 1		Did reaction reappear after reintroduction? 1	
Start Date 1		Stop Date 1	Ongoing
Batch/Lot number 1		Expiry Date 1	
To be completed only if used of the approved product labelli	Is it intentional? for a therapeutic p	at the initia urpose?	itive of
Suspect Product 2			
Trade Name 2		Active Ingredient 2	
Formulation 2		Indication 2	
Location of Administration 2		Route of administration 2	
Dosage Details 2 (dose, unit)		Action taken 2	
Dosage Frequency 2		Did reaction reappear after reintroduction? 2	
Start Date 2		Stop Date 2	Ongoing
Batch/Lot number 2		Expiry Date 2	
Suspect Product 3			
Trade Name 3		Active Ingredient 3	
Formulation 3		Indication 3	
Location of Administration 3		Route of administration 3	
Dosage Details 3 (dose, unit)		Action taken 3	
Dosage Frequency 3		Did reaction reappear after reintroduction? 3	
Start Date 3		Stop Date 3	Ongoing
Batch/Lot number 3		Expiry Date 3	
Suspect Product 4			
Trade Name 4		Active Ingredient 4	
Formulation 4		Indication 4	
Location of Administration 4		Route of administration 4	
Dosage Details 4 (dose, unit)		Action taken 4	
Dosage Frequency 4		Did reaction reappear after reintroduction? 4	
Start Date 4		Stop Date 4	Ongoing
Batch/Lot number 4		Expiry Date 4	



Page: 3 of 5

Adverse Event 1					
Event Verbatim 1				Event Outcome 1	
Event resulted in Death? 1		Congenital Anomaly?1		Onset Date 1	
Life threatening? 1		Resulted in Hospitalization 1		End Date 1	Ongoing
Disability? 1	Required Medical Intervention?		ı	Transmission of an Infect	ious agent via product 1
Causality 1 to Suspect Prod	duct 1	C	ausality	y 1 to Suspect Product 2	
Causality 1 to Suspect Prod	duct 3	C	Causality 1 to Suspect Product 4		

ongenital Anomaly? 2		Event Outcome 2 Onset Date 2	
ongenital Anomaly? 2		Onset Date 2	
		Offset Date 2	
Resulted in Hospitalization 2		End Date 2	Ongoing
Required Medical Intervention? 2		Transmission of an Infect	tious agent via product 2
Са	usality	y 2 to Suspect Product 2	
Ca	usality	y 2 to Suspect Product 4	
_	equired Medical Intervention? 2	equired Medical Intervention? 2	

Adverse Event 3							
Event Verbatim 3				Event Outcome 3			
Event resulted in Death? 3		Congenital Anomaly? 3		Onset Date 3			
Life threatening? 3		Resulted in Hospitalization 3		End Date 3	Ongoing		
Disability? 3		Required Medical Intervention? 3		Transmission of an Infect	ious agent via product 3		
Causality 3 to Suspect Product 1		C	Causality	y 3 to Suspect Product 2			
Causality 3 to Suspect Product 3		Causality 3 to Suspect Product 4					
					1		

			Event Outcome 4	
	Congenital Anomaly? 4		Onset Date 4	
	Resulted in Hospitalization 4		End Date 4	Ongoing
	Required Medical Intervention? 4		Transmission of an Infect	ious agent via product 4
luct 1	C	ausality	y 4 to Suspect Product 2	
luct 3	Causality 4 to Suspect Product 4			
		Resulted in Hospitalization 4 Required Medical Intervention? 4 uct 1 C	Resulted in Hospitalization 4 Required Medical Intervention? 4 uct 1 Causality	Congenital Anomaly? 4 Resulted in Hospitalization 4 Required Medical Intervention? 4 Causality 4 to Suspect Product 2



Page: 4 of 5

If the Outcome is Fatal, I	please provide De	eath Deta	ails:		
Date of Death					
Autopsy performed?	Cause(s		s) of Death		
Autopsy Report available? if yes please attach					
Concomitant Product 1					
Trade name C1					
Active Ingredient C1			Indication	C1	
Formulation C1			Route of ad	ministration C1	
Dosage Details C1 (dose, unit)			Dosage Fr	equency C1	
Start Date C1			Stop date	C1	Ongoing
Concomitant Product 2					
Trade name C2					
Active Ingredient C2			Indication	C2	
Formulation C2			Route of ad	ministration C2	
Dosage Details C2 (dose, unit)			Dosage Frequency C2		
Start Date C2			Stop date C2		Ongoing
Concomitant Product 3					
Trade name C3					
Active Ingredient C3			Indication	C3	
Formulation C3			Route of ad	ministration C3	
Dosage Details C3 (dose, unit)			Dosage Fr	equency C3	
Start Date C3			Stop date	C3	Ongoing
Concomitant Product 4					
Trade name C4					
Active Ingredient C4			Indication C4		
Formulation C4			Route of administration C4		
Dosage Details C4 (dose, unit)			Dosage Frequency C4		
Start Date C4			Stop date C4		Ongoing
Concomitant Product 5					
Trade name C5					
Active Ingredient C5			Indication	C5	
Formulation C5			Route of ad	ministration C5	
Dosage Details C5 (dose, unit)			Dosage Fr	equency C5	
Start Date C5			Stop date	C5	Ongoing

S	a	n	0	fi
•	$\mathbf{}$		$\mathbf{\circ}$	

Page: 5 of 5

Additional Information: Please provide additional details such as signs & symptoms, progression, possible causes that may explain the occurrence of the Adverse Event, vaccination details, family history, past drug history, corrective treatments, severity